SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the first quarter ended March 31, 2006. For the first quarter 2006, revenues from the sale of ZADAXIN®, SciClone’s lead product, increased by 17% to $7,789,000, compared with ZADAXIN revenues of $6,661,000 reported for the first quarter 2005. This increase in product revenues for the first quarter 2006 is primarily attributable to an increase in the quantity of ZADAXIN sold to the Chinese market, which accounts for over 90% of overall ZADAXIN sales. Contract revenue for the first quarter 2006 was $90,000 compared with $134,000 for the first quarter 2005.
